Crossmark

Ceftazidime–avibactam drives mutations, insertion, or overexpression in blaKPC-2 and enhances biofilm-forming ability of KPC-producing Klebsiella pneumoniae

Crossref DOI link: https://doi.org/10.1038/s41598-026-52233-z

Published Online: 2026-05-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jun

Liu, Zhaojun

Wang, Haolan

Xia, Yubing

Hu, Yongmei

Wang, Haichen

Xia, Fengjun

Zou, Mingxiang
Funding

Funding for this research was provided by:

Natural Science Foundation of Hunan Province (2023JJ30900)

Natural Science Foundation of Hunan Province (2022JJ70084)

Merck Sharp & Dohme (100759)
License Information

Text and Data Mining valid from 2026-05-12

Version of Record valid from 2026-07-13
More Information

Article History

Received: 3 November 2025

Accepted: 4 May 2026

First Online: 12 May 2026

Declarations

:

: The authors declare no competing interests.

: The study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Research Medical Ethics Subcommittee of the Medical Ethics Committee of Xiangya Hospital, Central South University (ID 202209541). All methods were performed in accordance with the relevant guidelines and regulations.

: Written informed consent was obtained from the participants enrolled in the study.

Document is current

Any future updates will be listed below